Aarti Drugs posts Q1 FY26 PAT higher at Rs. 54 Cr
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
This achievement underscores our unwavering commitment to upholding the highest standards of quality, safety, and regulatory compliance
Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products
The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026
The program will offer a structured and immersive learning experience for over 20,000 healthcare professionals across more than 10 cities
The global TCIM market is expected to reach nearly US$ 600 billion by 2025
Azelis will strengthen its presence in the domestic market by leveraging portfolio synergies, actively consolidating the business, and creating value for all stakeholders
Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need
Subscribe To Our Newsletter & Stay Updated